Table 1.
Descriptive characteristics of the main cohort with a comparison between the group with negative and positive lymph nodes.
| Overall | pN0 | pN1 | p-value | |
|---|---|---|---|---|
| Patients, overall, n (%) | 752 (100%) | 674 (89.6%) | 78 (10.4%) | |
| Median age at surgery, years (IQR) | 65 (60–69) | 65 (60–69) | 64 (60–68) | 0.65 |
| Median preoperative PSA, ng/mL (IQR) | 7 (5.15–10) | 6.77 (5.08–9.4) | 10.18 (7.37–16) | <0.0001 |
| Clinical stage at DRE, n (%) | ||||
| cT1c | 540 (71.8%) | 502 (74.5%) | 38 (48.2%) | <0.0001 |
| cT2 | 169 (22.5%) | 139 (20.6%) | 30 (38.5%) | |
| cT3 | 43 (5.7%) | 33 (4.9%) | 10 (13%) | |
| Patients with positive mpMRI, n (n%) | 327 (100%) | 286 (87.5%) | 41 (12.5%) | |
| Median max. index lesion diameter on mpMRI, mm (IQR) | 11 (8–14) | 10 (8–13) | 14 (12–20) | <0.0001 |
| PI-RADS score for index lesion, n (%) | <0.0001 | |||
| 3 | 45 (14%) | 44 (15%) | 2 (4.2%) | |
| 4 | 178 (54.5%) | 166 (58%) | 13 (31.2%) | |
| 5 | 104 (31.5%) | 76 (27%) | 26 (64.6%) | |
| Clinical stage at MRI, n (%) | <0.0001 | |||
| cT2 | 274 (83.7%) | 253 (88.2%) | 21 (52%) | |
| cT3a | 36 (10.9%) | 28 (9.8%) | 8 (18.8%) | |
| cT3b | 17 (5.4%) | 5 (1.7%) | 12 (29.2%) | |
| Median number of cores taken, overall, n (IQR) | 14 (12–15) | 14 (12–15) | 14 (11–15) | 0.8 |
| Median number of pos. cores, overall, n (IQR) | 5 (3–7) | 4 (3–6) | 7 (5–10) | <0.0001 |
| ISUP Grade Group on biopsy, overall, n (%) | <0.0001 | |||
| 1 | 201 (26.7%) | 196 (29.1%) | 5 (5.9%) | |
| 2 | 305 (40.6%) | 291 (43.2%) | 13 (17.6%) | |
| 3 | 125 (16.6%) | 102 (15%) | 24 (30.6%) | |
| 4 | 85 (11.3%) | 63 (9.4%) | 22 (28.2%) | |
| 5 | 36 (4.8%) | 22 (3.3%) | 14 (17.7%) | |
| Median number of pos. systematic cores, n (IQR) | 3 (2–6) | 3 (2–5) | 5 (3–8) | <0.0001 |
| Median perecent. (%) of pos. systematic cores with csPCa, n (IQR) | 21.5%(0–42.5%) | 17%(0–41%) | 50%(30–92%) | <0.0001 |
| Median number of pos. targeted cores, n (IQR) | 2 (1–3) | 2 (1–3) | 3 (2–4) | <0.0001 |
| ISUP Grade Group on MRI-targeted biopsy, n (%) | <0.0001 | |||
| 1 | 56 (17.2%) | 58 (20.1%) | 1 (2%) | |
| 2 | 139 (42.5%) | 134 (47%) | 7 (17.4%) | |
| 3 | 61 (18.5%) | 49 (17.2%) | 11 (27.5%) | |
| 4 | 45 (13.7%) | 31 (10.9%) | 12 (27.6%) | |
| 5 | 26 (8%) | 14 (4.8%) | 10 (25.5%) | |
| Pathological Grade Group, overall, n (%) | <0.0001 | |||
| 1 | 110 (14.6%) | 106 (15.7%) | 4 (4.9%) | |
| 2 | 348 (46.1%) | 344 (50.8%) | 4 (4.9%) | |
| 3 | 173 (23%) | 149 (22.2%) | 24 (30.5%) | |
| 4 | 67 (9.1%) | 48 (7.2%) | 19 (25.1%) | |
| 5 | 54 (7.2%) | 27 (4.1%) | 27 (34.6%) | |
| Pathological Stage, overall, n (%) | <0.0001 | |||
| pT2 | 481 (64%) | 469 (69.6%) | 12 (15.4%) | |
| pT3a | 161 (21.3%) | 141 (20.9%) | 20 (25.6%) | |
| pT3b | 110 (14.7%) | 64 (9.5%) | 46 (59%) | |